Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Las Vegas, NV
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Lebanon, NH
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Lebanon, NH
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Calabash, NC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Calabash, NC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Tabor City, NC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Tabor City, NC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Columbus, OH
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Columbus, OH
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Marion, OH
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Marion, OH
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Zanesville, OH
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Zanesville, OH
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Eugene, OR
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Eugene, OR
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Philadelphia, PA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Warwick, RI
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Warwick, RI
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigational Site
mi
from
Charleston, SC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Columbia, SC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Columbia, SC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Greer, SC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Greer, SC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
N. Myrtle Beach, SC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
N. Myrtle Beach, SC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Boerne, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Boerne, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
El Paso, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
El Paso, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Houston, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Houston, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Houston, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Kingwood, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Kingwood, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis
mi
from
San Antonio, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis
mi
from
San Antonio, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
White River Junction, VT
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
White River Junction, VT
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Burke, VA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Burke, VA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Fredericksburg, VA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Manassas, VA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Manassas, VA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Richmond, VA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Richmond, VA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Oregon, WI
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Oregon, WI
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Greenville, SC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Exercise Training Study for Patients With Cystic Fibrosis
Self-Regulated Exercise in CF: A Randomized Trial
Status: Enrolling
Updated:  2/18/2016
Antiono J & Janet Palumbo Cystic Fibrosis Center; Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Exercise Training Study for Patients With Cystic Fibrosis
Self-Regulated Exercise in CF: A Randomized Trial
Status: Enrolling
Updated: 2/18/2016
Antiono J & Janet Palumbo Cystic Fibrosis Center; Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Matrix Institute on Addictions
mi
from
Los Angeles, CA
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Matrix Institute on Addictions
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Friends Research Institute
mi
from
Torrance, CA
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Friends Research Institute
mi
from
Torrance, CA
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
VA Medical Center
mi
from
Denver, CO
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
VA Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
University of Miami School of Medicine
mi
from
Miami, FL
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
University of Miami School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
NeuroPsychiatric Research & Practice Assoc., Ltd.
mi
from
Oak Brook, IL
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
NeuroPsychiatric Research & Practice Assoc., Ltd.
mi
from
Oak Brook, IL
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Mountain Manor Treatment Center at Baltimore
mi
from
Baltimore, MD
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Mountain Manor Treatment Center at Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Boston University School of Medicine
mi
from
Boston, MA
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Boston University School of Medicine
mi
from
Boston, MA
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Pacific Institute for Research and Evaluation
mi
from
Albuquerque, NM
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Pacific Institute for Research and Evaluation
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Western Psychiatric Inst. and Clinic
mi
from
Pittsburgh, PA
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Western Psychiatric Inst. and Clinic
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Medical University of South Carolina
mi
from
Charleston, SC
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Pillar Clinical Research, LLC
mi
from
Dallas, TX
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Pillar Clinical Research, LLC
mi
from
Dallas, TX
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
George E. Wahlen VA Medical Center
mi
from
Salt Lake City, UT
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
George E. Wahlen VA Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated:  2/23/2016
The Hartford Hospital
mi
from
Hartford, CT
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated: 2/23/2016
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated:  2/23/2016
MedStar Washington Hospital Center
mi
from
Washington,
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated: 2/23/2016
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated:  2/23/2016
St. Joseph's Hospitals
mi
from
Tampa, FL
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated: 2/23/2016
St. Joseph's Hospitals
mi
from
Tampa, FL
Click here to add this to my saved trials
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated:  2/23/2016
Legacy Good Samaritan
mi
from
Portland, OR
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated: 2/23/2016
Legacy Good Samaritan
mi
from
Portland, OR
Click here to add this to my saved trials
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated:  2/23/2016
Legacy Salmon Creek Medical Center
mi
from
Vancouver, WA
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated: 2/23/2016
Legacy Salmon Creek Medical Center
mi
from
Vancouver, WA
Click here to add this to my saved trials
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Status: Enrolling
Updated:  2/24/2016
William S. Middleton Memorial Veterans Hospital, Madison, WI
mi
from
Madison, WI
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Status: Enrolling
Updated: 2/24/2016
William S. Middleton Memorial Veterans Hospital, Madison, WI
mi
from
Madison, WI
Click here to add this to my saved trials